← Eichor
Study identifier: NCT06331208 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Mechanisms of Pulmonary Vascular Dysfunction in Heart Failure

Condition: Heart Failure · Pulmonary Hypertension · Pulmonary Vascular Resistance Abnormality  ·  Sponsor: Institute for Clinical and Experimental Medicine

PhaseN/A
Planned participants230
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Heart failure (HF) patients often develop pulmonary hypertension (PH) that leads to transition into a biventricular HF with poor prognosis. There are two PH components: 1) passive transmission of increased left atrial pressure, 2) heart failure (HF) related pulmonary vascular dysfunction (PVD) with increased vascular resistance. Intriguingly, only some, but not all HF patients develop heart failure-related PVD. The mechanisms and non-invasive detection of HF-PVD are poorly understood and are the focus of the current grant application. Development of PVD is linked to insufficiently characterized metabolic factors that may be mediators of HF-PVD. Untargeted metabolomics is an emerging powerful platform for the discovery of pathways linked to diseases. Its specificity can be further enhanced using transpulmonary gradient sampling. Part A of the project aims to identify novel metabolites associated with the presence of PVD in patients with HF that can serve as biomarkers or targets and will provide biologic insights into PVD. Part C will assess the effects of reverting of metabolic alterations (identified in part A) by a drug/diet on pulmonary vasculature in experimental HF-related PVD. The "gold standard" for the detection of PVD is right heart catheterization, which is invasive and risky. Heart failure-related PVD is therefore often diagnosed late. There is a need for noninvasive tests that may help to detect PVD in early stages and can be done repeatedly. Recent advances i…

This description comes directly from the study's public registry record.

Talk to the study team

Vojtech Melenovsky, MD, PhD  ·  420 236055190  ·  vome@ikem.cz

Always discuss trial participation with your own doctor first.

Locations (1)

Institute for Clinical and Experimental Medicine - IKEMPrague, CzechiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06331208